NTRA: מכפיל מחיר לרווח לצמיחה natera.com
Innovative genetic analysis systems in oncology and reproduction are experiencing a rapid surge. The valuation adequacy ratio relative to growth rates indicates that the metric has reached the level of 0.00. Dominance in prenatal diagnostics and insurance coverage ensure stable FCF. The advantage of Natera, Inc. (NTRA) is based on unique genomic data sets that create a sustainable cash flow.
פילוחי מדדים ואנליטיקה של חברת Natera, Inc. (NTRA)
The PEG ratio compares the P/E multiple with earnings growth, identifying an undervalued asset when the value is below one. An analysis of the P/E valuation relative to business expansion rates confirms the potential of Natera, Inc. (NTRA), as unique patented oncology diagnostic methods create a high barrier to entry, allowing the company to exercise pricing power with insurance providers and accelerate earnings growth.
